// App-Quantinova.ai

1056 : Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models

Researchers

Presenter

  • Christopher J. Hindley

Principal Investigators

  • Lynsey Fazal

  • Joanne M. Munck

  • Vanessa Martins

  • Alpesh D. Shah

  • Nicola E. Wilsher

  • Nicola G. Wallis

  • Harold N. Keer

  • John F. Lyons

Medical Centers

  • Astex Pharmaceutical, Inc., Cambridge, United Kingdom.

  • Astex Pharmaceuticals, Inc., Pleasanton, CA

Locations

  • United Kingdom

  • United States

Companies

  • Astex Pharmaceutical

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

  • Melanoma

Biomarkers

  • Mitogen-activated protein kinase 3

  • Extracellular signal-regulated kinase

  • GTPase Nras

  • HRas Proto-Oncogene, GTPase

  • KRAS proto-oncogene, GTPase

  • Ribosomal Protein S6 Kinase A1

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT03520075

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved